A community-based pneumococcal vaccination program in Sera Town, Japan, significantly reduced pneumonia-related mortality among older adults by 25%, according to a study published in the Journal of Epidemiology on May 5, 2025. The initiative, launched in 2010 ahead of Japan’s national rollout, highlights the potential of localized vaccination efforts to combat pneumonia, a leading cause of death in aging populations.
Pneumonia claims approximately 74,000 lives annually in Japan, with 98% of deaths occurring in people aged 65 and older. The bacteria Streptococcus pneumoniae are the primary culprit. In 2010, Sera Town partnered with Hiroshima University to implement a vaccination support program for residents aged 65 and older, using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The program ran until 2015 and included a five-year follow-up to evaluate its impact.
Researchers analyzed vital statistics data from 2000 to 2016, employing an interrupted time series analysis to compare mortality trends before and after the program. The results revealed a 25% decline in pneumonia-related deaths and a reversal of the previously rising mortality trend. The incidence rate of pneumonia among vaccinated individuals was 20.3 cases per 1,000 person-years—a metric reflecting follow-up time across participants.
“This program reversed the increasing trend in pneumonia mortality in the community,” said Dr. Aya Sugiyama, lead author and lecturer at Hiroshima University. “These findings underscore the public health value of local vaccination efforts, especially in super-aged societies like Japan.”
The study provides real-world evidence supporting the effectiveness of community-driven vaccination programs in reducing pneumonia deaths among the elderly. As Japan faces unprecedented aging, the findings could guide future public health strategies. The team plans to share their results to inform broader discussions on preventive care for aging populations worldwide.
Add comment